Biotechnology Value Fund L P's Form 4 filing
Repare Therapeutics Inc.RPTX · filed Nov 3, 2023
- Accession no.
- 0000921895-23-002458
- Filed
- Nov 3, 2023, 5:37 PM ET
- Trade date
- Nov 2, 2023
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market purchases total $2.82M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Biotechnology Value Fund L PCIK 0000918923 | 10% Owner |
| BVF Partners L PCIK 0001055947 | 10% Owner |
| BVF IncCIK 0001056807 | 10% Owner |
| Biotechnology Value Fund II LPCIK 0001102444 | Other: See Explanation of Responses |
| Lampert Mark NCIK 0001233840 | 10% Owner |
| Biotechnology Value Trading Fund OS LPCIK 0001660683 | Other: See Explanation of Responses |
| BVF Partners OS Ltd.CIK 0001660684 | Other: See Explanation of Responses |
| BVF I GP LLCCIK 0001803805 | 10% Owner |
| BVF II GP LLCCIK 0001803806 | Other: See Explanation of Responses |
| BVF GP Holdings LLCCIK 0001803809 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 2, 2023 | Common Shares, no par value | PPurchaseAcquired | +218,979 | $3.60 | +$788,324.4 | 4,662,402 | Direct | |
| Nov 2, 2023 | Common Shares, no par value | PPurchaseAcquired | +492,251 | $3.60 | +$1,772,103.6 | 3,792,157 | Direct | |
| Nov 2, 2023 | Common Shares, no par value | PPurchaseAcquired | +72,479 | $3.60 | +$260,924.4 | 485,083 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.